A draft US policy would let licensed compounding pharmacies prepare six wellness peptides on prescription, and an Indian endocrinologist warns that sellers elsewhere are likely to misread it as medical validation. US Health Secretary Robert F. Kennedy Jr. announced the draft, under which the government would not take enforcement action against pharmacies and physicians meeting specified requirements.

The six are BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax. None has been approved by the US Food and Drug Administration, and the policy changes how access is regulated rather than what the evidence shows.

What the proposal actually allows

Pharmacies would have to source ingredients from traceable manufacturers, meet quality testing requirements and report serious side effects. Each preparation could contain only one of the six, so peptide stacks would fall outside the carve-out entirely.

That is real oversight of how a product is made and supplied, and it is worth something. It is not the FDA review process, which weighs trial findings, manufacturing quality and whether benefits outweigh risks before anything is approved.

Where the evidence stops

BPC-157, nicknamed the "Wolverine peptide" after the comic character, is promoted for tendon, muscle and gut repair, mostly on the back of animal experiments. The frequently cited knee pain study reviewed 17 patients, of whom 16 were contacted, with no comparison group and no standard measurement tools.

FDA reviewers found insufficient evidence to establish TB-500's effectiveness for wound healing, and research on the related molecule thymosin beta-4 is a different substance being used to argue a case. MOTS-c has shown effects on insulin sensitivity in mice, Epitalon claims rest on telomere markers rather than outcomes, and KPV lacks adequate human evidence of benefit or safety.

Purity is not proof

Supporters argue people are already buying vials labeled research use only, so licensed supply improves accountability. Bhattacharya's counter is the sharpest line in the piece: a laboratory can confirm a vial contains the stated chemical, but it cannot show whether months of treatment damage an organ or interact with another medicine.

Bottom line

American enforcement discretion does not confer regulatory approval in India, where Telangana's drug safety authority warned on October 14 against unapproved weight loss drugs and experimental peptides, naming BPC-157. What remains unsettled is the thing no policy change can supply: clinical results.